Loading…
Blue Jet Healthcare (BLUEJET)₹543.55−4.63%Pharmaceuticals
In the Jun 2026 quarter (standalone), Blue Jet Healthcare reported sales of ₹293 Cr, down 17.4% from Jun 2025, and net profit of ₹77.90 Cr, down 14.3% year on year. For the year to Mar 2026, sales were ₹946 Cr and net profit ₹248 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 | 165 | 192 | 235 | 293 |
| Expenses | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 233 | 111 | 146 | 163 | 194 |
| Operating Profit | 62.91 | 54.94 | 52.92 | 43.91 | 68.87 | 124 | 140 | 121 | 54.91 | 46.96 | 70.95 | 97.84 |
| OPM % | 35.1% | 33.1% | 29.0% | 27.1% | 33.1% | 39.0% | 41.1% | 34.0% | 33.1% | 24.1% | 30.1% | 33.1% |
| Other Income | 7.99 | −2.99 | 8.99 | 8.99 | 11.99 | 12.99 | 11.99 | 7.99 | 23.99 | 12.99 | 22.99 | 14.98 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 4.99 | 0.00 | 0.99 | 0.99 |
| Depreciation | 5.99 | 7.99 | 7.98 | 2.99 | 4.99 | 4.99 | 4.99 | 5.98 | 5.99 | 5.99 | 5.99 | 6.98 |
| Profit before tax | 63.96 | 43.93 | 53.92 | 48.95 | 76.90 | 132 | 147 | 123 | 68.88 | 53.94 | 86.94 | 106 |
| Tax % | 26.0% | 27.0% | 27.0% | 24.0% | 24.0% | 25.0% | 25.0% | 26.0% | 24.0% | 25.0% | 26.0% | 26.0% |
| Exceptional items | 0.00 | −7.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 47.96 | 31.94 | 39.94 | 37.93 | 57.92 | 98.92 | 110 | 90.86 | 51.91 | 39.94 | 63.89 | 77.90 |
| EPS (Rs) | 2.75 | 1.84 | 2.28 | 2.17 | 3.35 | 5.70 | 6.33 | 5.25 | 3.00 | 2.31 | 3.70 | 4.50 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 538 | 499 | 683 | 721 | 712 | 1,030 | 946 | 885 |
| Expenses | 324 | 291 | 433 | 500 | 479 | 650 | 652 | 614 |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 377 | 294 | 271 |
| OPM % | 40.0% | 41.0% | 36.1% | 30.0% | 32.0% | 37.1% | 31.1% | 30.6% |
| Other Income | 5.99 | 8.99 | 18.98 | 23.98 | 17.98 | 45.97 | 68.99 | 74.95 |
| Interest | 6.98 | 4.99 | 2.99 | 0.99 | 0.00 | 0.00 | 5.98 | 6.97 |
| Depreciation | 17.96 | 19.95 | 21.94 | 24.96 | 27.93 | 17.96 | 23.95 | 24.95 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 | 406 | 333 | 316 |
| Tax % | 25.0% | 26.0% | 25.0% | 26.0% | 26.0% | 25.0% | 25.0% | — |
| Exceptional items | 0.00 | 0.99 | 0.00 | 1.01 | −7.01 | 6.01 | 0.00 | 0.00 |
| Net Profit | 145 | 142 | 182 | 160 | 164 | 305 | 248 | 234 |
| EPS (Rs) | 24,052.84 | 1,425.38 | 10.44 | 9.21 | 9.42 | 17.54 | 14.27 | 13.51 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 11.0% | 7.0% | 8.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.60 | 10.02 | 35.07 | 34.99 | 34.95 | 35.02 | 34.96 |
| Reserves | 199 | 331 | 489 | 649 | 813 | 1,101 | 1,328 |
| Borrowings | 74.15 | 52.15 | 19.05 | 5.00 | 3.00 | 21.03 | 41.99 |
| Other Liabilities | 92.44 | 143 | 174 | 177 | 212 | 264 | 240 |
| Total Liabilities | 365 | 536 | 715 | 864 | 1,061 | 1,422 | 1,645 |
| Fixed Assets | 107 | 140 | 157 | 152 | 173 | 301 | 317 |
| CWIP | 1.99 | 2.99 | 2.99 | 29.89 | 147 | 88.75 | 300 |
| Investments | 26.07 | 37.08 | 94.16 | 190 | 250 | 188 | 253 |
| Other Assets | 230 | 356 | 462 | 492 | 491 | 844 | 774 |
| Inventories | 69.16 | 118 | 105 | 126 | 130 | 264 | 188 |
| Trade receivables | 118 | 144 | 228 | 240 | 177 | 351 | 340 |
| Cash & equivalents | 14.94 | 69.74 | 87.63 | 65.70 | 84.65 | 120 | 148 |
| Total Assets | 365 | 536 | 715 | 864 | 1,061 | 1,422 | 1,645 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 122 | 137 | 146 | 142 | 240 | 45.90 | 333 |
| Cash from investing activity | −44.91 | −60.82 | −75.87 | −147 | −264 | −34.94 | −275 |
| Cash from financing activity | −71.69 | −20.91 | −55.78 | −3.98 | −1.99 | −18.91 | −30.88 |
| Net cash flow | 5.01 | 55.08 | 14.01 | −10.02 | −24.03 | −8.01 | 28.01 |
| Capex | 16.03 | 52.07 | 23.02 | 59.06 | 174 | 80.10 | 220 |
| Free cash flow | 106 | 84.85 | 125 | 82.86 | 67.93 | −33.95 | 115 |
| CFO / OP % | 80.1% | 66.0% | 70.1% | 92.1% | 109.0% | 36.0% | 151.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 80 | 105 | 121 | 121 | 91 | 124 | 131 |
| Inventory days | 121 | 254 | 134 | 138 | 152 | 210 | 158 |
| Days payable | 90 | 128 | 72 | 58 | 35 | 70 | 48 |
| Cash conversion cycle | 111 | 232 | 184 | 200 | 207 | 263 | 241 |
| Working capital days | 54 | 88 | 102 | 119 | 91 | 156 | 223 |
| ROCE % | — | 58.0% | 53.0% | 35.0% | 30.0% | 40.0% | 26.0% |
For the Jun 2026 quarter, Blue Jet Healthcare reported sales of ₹293 Cr, down 17.4% year on year and net profit of ₹77.90 Cr, down 14.3% year on year. The operating margin was 33.1%.
Blue Jet Healthcare's sales for the year to Mar 2026 were ₹946 Cr; over the last twelve months they were ₹885 Cr.
Net profit for the year to Mar 2026 was ₹248 Cr, and ₹234 Cr over the last twelve months. Earnings per share over the same trailing period were ₹13.51.
Blue Jet Healthcare reported borrowings of ₹41.99 Cr at Mar 2026, against cash and equivalents of ₹148 Cr.
Cash from operations was ₹333 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹115 Cr.